Relatively poor outcomes for very young women in these studies were attributed to a number of factors including incomplete chemotherapy-induced amenorrhea, nonadherence to treatment, lower ER expression levels, hormone resistance, elevated Ki67 levels and higher tumor grade. This evidence concerns the gene ESR1 and neoplasm.